These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 2000673)
41. [Prostatic cancer. Reliability of clinical staging and the prognostic significance of age, clinical stage and tumor morphology]. Mihatsch MJ; Rist M; Ohnacker H; Oberholzer M; Spichtin HP; Schmassmann A; Perret A; Torhorst J; Rutishauser G Z Urol Nephrol; 1983 May; 76(5):281-97. PubMed ID: 6880416 [No Abstract] [Full Text] [Related]
42. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
43. Prognostic influence of the third Gleason grade in prostatectomy specimens. Cedeño Díaz OM; Fernández Aceñero MJ; Alvarez Fernández E Urol Oncol; 2012; 30(4):386-90. PubMed ID: 21292510 [TBL] [Abstract][Full Text] [Related]
44. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Vartanian RK; Weidner N Lab Invest; 1995 Dec; 73(6):844-50. PubMed ID: 8558846 [TBL] [Abstract][Full Text] [Related]
45. [Clinical studies on endocrine therapy of prostatic carcinoma (3): Histopathological features of prostatic carcinoma and its prognosis]. Kumamoto Y; Tsukamoto T; Umehara T; Harada M; Shimazaki J; Fuse H; Oshima H; Takeuchi H; Yoshida O; Okada K Hinyokika Kiyo; 1990 Mar; 36(3):295-305. PubMed ID: 2191571 [TBL] [Abstract][Full Text] [Related]
46. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. McKenney JK; Wei W; Hawley S; Auman H; Newcomb LF; Boyer HD; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Tretiakova MS; Vakar-Lopez F; Carroll PR; Cooperberg MR; Gleave ME; Lance RS; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; Brooks JD Am J Surg Pathol; 2016 Nov; 40(11):1439-1456. PubMed ID: 27635949 [TBL] [Abstract][Full Text] [Related]
47. Prognostic criteria in patients with prostate cancer: Gleason score versus volume-weighted mean nuclear volume. Fujikawa K; Sasaki M; Arai Y; Yamabe H; Ogawa O; Yoshida O Clin Cancer Res; 1997 Apr; 3(4):613-8. PubMed ID: 9815728 [TBL] [Abstract][Full Text] [Related]
48. Updates on Grading and Staging of Prostate Cancer. Braunhut BL; Punnen S; Kryvenko ON Surg Pathol Clin; 2018 Dec; 11(4):759-774. PubMed ID: 30447840 [TBL] [Abstract][Full Text] [Related]
49. [Predicting factors of tumor organ-confinement in adenocarcinoma of the prostate]. Borque Fernando A; Allepuz Losa C; Del Agua Arias C; Valdivia Navarro P; Ascaso Cornago I; Rioja Sanz LA Actas Urol Esp; 1997 Oct; 21(9):890-7. PubMed ID: 9471872 [TBL] [Abstract][Full Text] [Related]
50. [Reproducibility of malignancy grading in prostatic cancers using the Gleason-Böckling system]. Kiss F; Lakner G; Csellár M; Nagy P; Tóth A; Vittay G Orv Hetil; 1997 May; 138(19):1195-9. PubMed ID: 9235527 [TBL] [Abstract][Full Text] [Related]
51. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies. Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771 [TBL] [Abstract][Full Text] [Related]
54. Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer. Madani SH; Ameli S; Khazaei S; Kanani M; Izadi B Indian J Pathol Microbiol; 2011; 54(4):688-91. PubMed ID: 22234091 [TBL] [Abstract][Full Text] [Related]
55. [Study of incidental carcinoma of the prostate. Part 1. Pathological analysis related to the clinical features]. Fujita T; Kanimoto Y; Akino H; Okada K; Shiraishi T; Nakakuki K Hinyokika Kiyo; 1991 Jul; 37(7):695-703. PubMed ID: 1927769 [TBL] [Abstract][Full Text] [Related]
56. Significance of p53 and ki-67 expression in prostate cancer. Verma R; Gupta V; Singh J; Verma M; Gupta G; Gupta S; Sen R; Ralli M Urol Ann; 2015; 7(4):488-93. PubMed ID: 26692671 [TBL] [Abstract][Full Text] [Related]
57. Aid to accurate clinical staging-histopathologic grading in prostatic cancer. Thomas R; Lewis RW; Sarma DP; Coker GB; Rao MK; Roberts JA J Urol; 1982 Oct; 128(4):726-8. PubMed ID: 7143593 [TBL] [Abstract][Full Text] [Related]
58. [Retrospective clinical evaluation of prognosis factors in stage D2 prostatic cancer treated with endocrine therapy]. Kudo K; Nagata M; Hayashi N; Imamura H; Kimura M; Mimura H; Matsuyama K; Shishido S; Chino I Hinyokika Kiyo; 1991 Feb; 37(2):129-34. PubMed ID: 1710871 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Maygarden SJ; Novotny DB; Moul JW; Bae VL; Ware JL Mod Pathol; 1994 Dec; 7(9):930-6. PubMed ID: 7892162 [TBL] [Abstract][Full Text] [Related]